Opioid Rotation: Fentanyl Patch → Extended‑Release Oral Morphine

Conversion Equivalence

• The National Comprehensive Cancer Network (NCCN) guideline states that a 50 µg/hour transdermal fentanyl patch is equivalent to 120 mg per day of oral morphine. 1

Dose Calculation for Q8‑Hour Regimen

• Dividing the total daily morphine requirement (120 mg) by three 8‑hour intervals yields an individual dose of 40 mg per administration. 1

Incomplete Cross‑Tolerance Adjustment

• NCCN recommends reducing the calculated equianalgesic dose by 25 %–50 % when rotating between opioids to account for incomplete cross‑tolerance. 1
• Applying a 50 % reduction to the 40 mg dose results in a starting dose of 20 mg every 8 hours. 2
• Applying a 25 % reduction to the 40 mg dose results in a starting dose of 30 mg every 8 hours. 2

Recommended Starting Dose

• Based on the above reductions, the NCCN guideline advises initiating extended‑release oral morphine at 20 mg–30 mg every 8 hours. 1

Breakthrough Pain Management

• For breakthrough pain, NCCN recommends immediate‑release morphine at 10 %–20 % of the total daily dose (approximately 12 mg–24 mg), administered every 2–4 hours as needed. 3
• This supplemental dosing helps maintain adequate analgesia during the opioid transition, as noted by NCCN. 1

Titration Strategy & Monitoring

• If the patient’s pain was well‑controlled on the fentanyl patch, NCCN suggests starting with the more conservative 50 % reduction (20 mg q8h); if control was inadequate, a 25 % reduction (30 mg q8h) or the full equianalgesic dose may be used. 1
• NCCN advises close monitoring and upward titration based on the frequency of breakthrough medication use; persistent need for rescue doses indicates the baseline dose is insufficient. 4
• The American Society of Clinical Oncology (ASCO) emphasizes that opioid rotation often requires subsequent dose escalation after the initial conversion to achieve satisfactory pain relief. 5
• NCCN recommends reassessing pain control and side‑effects within 24 hours of conversion. 1

Safety Considerations

• NCCN cautions against using conversion tables in reverse (i.e., applying morphine‑to‑fentanyl tables for fentanyl‑to‑morphine conversion), as this can overestimate the morphine dose and increase the risk of fatal overdose. 1
• NCCN and the European Society for Medical Oncology (ESMO) advise avoiding codeine or morphine in patients with renal failure due to accumulation of neurotoxic metabolites; alternative opioids such as hydromorphone or fentanyl are recommended. 5

Variability & Clinical Judgment

• ESMO notes that conversion ratios exhibit considerable inter‑patient variability (reported ranges 70:1–100:1 for oral morphine to transdermal fentanyl) and that clinicians must apply judgment when finalizing dosing. 6

Fentanyl‑to‑Oral Morphine Conversion Guidelines

Transdermal Fentanyl Conversion Ratio

• The National Comprehensive Cancer Network (NCCN) states that the standard equianalgesic conversion ratio for transdermal fentanyl to oral morphine is 100 mg oral morphine per day per 1 µg/hour of fentanyl, meaning a 50 µg/hour fentanyl patch corresponds to approximately 120 mg oral morphine daily. This ratio is presented as a guideline recommendation. 7

Parenteral Fentanyl Conversion

• According to the NCCN guideline, 0.1–0.25 mg of parenteral fentanyl is roughly equivalent to 10 mg of parenteral morphine or 30 mg of oral morphine. The guideline provides this conversion range without specifying a single factor, reflecting moderate‑level evidence from expert consensus. 7

Renal Function Considerations

• The NCCN advises that in patients with renal impairment, fentanyl should be preferred over morphine because fentanyl lacks neurotoxic metabolites that accumulate in renal failure; this preference does not alter the established conversion ratio. This recommendation is based on guideline consensus. 7